Journal List > Ewha Med J > v.36(1) > 1058571

TOOLS
Oh, Lee, Chung, and Kim: Clinical Relevance of EGFR Mutations in Colorectal Cancer Patients
Original Article
The Ewha Medical Journal

The Ewha Medical Journal 2013; 36(1): 51-57.

Published online: 25 March 2013

DOI: https://doi.org/10.12771/emj.2013.36.1.51

Clinical Relevance of EGFR Mutations in Colorectal Cancer Patients

Bo-Young Oh, Ryung-Ah Lee, Soon-Sup Chung, Kwang Ho Kim

Department of Surgery, Ewha Womans University School of Medicine, Seoul, Korea.

Corresponding author: Kwang Ho Kim, Department of Surgery, Ewha Womans University School of Medicine, 911-1 Mok-dong, Yangcheon-gu, Seoul 158-710, Korea. Tel: 82-2-2650-5585, Fax: 82-2-2644-7984, eastgate@ewha.ac.kr

Copyright © 2013. Ewha Womans University School of Medicine

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives

The EGFR plays an important role in tumorigenesis and tumor progression of colorectal cancer, and leads to the activation of intracellular signaling pathways. The use of anti-EGFR-targeted therapy has increased for patients with colorectal cancer, but patients with EGFR mutations will be resistant to anti-EGFR-targeted therapy. The identification of gene mutations is critical in cancer treatment; therefore, the aim of this study is to investigate the incidences of EGFR mutations in colorectal cancer patients in Korea.

Methods

We reviewed 58 colorectal cancer patients who underwent operations between 2003 and 2006, retrospectively. We analyzed their EGFR mutations in 4 loci by DNA sequencing. In addition, we analyzed the correlation between the presence of EGFR mutation and patients' clinicopathologic features.

Results

Of the 58 patients, 35 patients were male and 23 were female. Their mean age was 63.28±11.18 years. Two patients (3.45%) were diagnosed as stage Tis, 7 patients (12.07%) had stage I, 24 patients (41.38%) had stage II, 20 patients (34.48%) had stage III, and 5 patients (8.62%) had stage IV. As a result of mutational analysis, EGFR mutations on exon 20 were detected in 13 patients (22.41%, G→A transitions). EGFR mutations on exon 18, 19 and 21 were not detected. EGFR mutation increased in the earlier stage and the absence of lymph node metastasis (P=0.028).

Conclusion

The incidence of EGFR mutation in Korean colorectal cancer patients is 22.41%. In addition, EGFR mutation significantly increased in the earlier stage and the absence of lymph node metastasis.

Keywords: Colorectal cancer, EGFR, Mutation

Figures and Tables

Fig. 1
Sequencing results for EGFR mutation. Partial nucleotide sequences of the wild and mutant in exon 20 of the EGFR gene. (A) Forward; transition of G to A (arrow) leading to substitute methionine for isoleucine (B) Reverse; transition of C to T (arrow).
emj-36-51-g001
Fig. 2
Overall survival and disease-free survival according to EGFR status. (A) There was no significant difference between EGFR-wild group and EGFR-mutated group on overall survival (P=0.8118). (B) EGFR mutational status was not associated with any significant influence on disease-free survival (P=0.8388).
emj-36-51-g002
Table 1
Primers used for amplification and sequencing of EGFR genes
emj-36-51-i001

*F, forward; †R, reverse.

Table 2
Patient's clinicopathologic features
emj-36-51-i002

*LN, lymph node; †Tis, tumor in situ.

Table 3
Relationship between EGFR mutation and the clinicopathologic features
emj-36-51-i003

*EGFR, epithelial growth factor receptor; †Tis, tumor in situ; ‡LN, lymph node.

Notes

This article is the Korean version of "Epidermal growth factor receptor mutations in colorectal cancer patients.". Secondary publication (J Korean Soc Coloproctol 2011,27:127-32 doi: 10.3393/jksc.2011.27.3.127).

References

1. de Castro-Carpeño J, Belda-Iniesta C, Casado Sáenz E, Hernández Agudo E, Feliu Batle J, González Barón M. EGFR and colon cancer: a clinical view. Clin Transl Oncol. 2008. 10:6–13.
2. Ponz-Sarvisé M, Rodríguez J, Viudez A, Chopitea A, Calvo A, García-Foncillas J, et al. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What's new? World J Gastroenterol. 2007. 13:5877–5887.
3. Sameer AS, Chowdhri NA, Abdullah S, Shah ZA, Siddiqi MA. Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: a report. Indian J Cancer. 2009. 46:219–225.
4. Yun SH. Molecular targeted therapy in colorectal cancer. J Korean Soc Coloproctol. 2004. 20:180–188.
5. Kim HA, Lee RA, Hwang DY, Park SH. The significances of EGFR overexpression in colorectal cancer. J Korean Soc Coloproctol. 2005. 21:36–41.
6. Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med. 2009. 24:48–54.
7. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005. 5:341–354.
8. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem. 1990. 265:7709–7712.
9. Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN, et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res. 2006. 66:404–411.
10. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol. 2001. 13:506–513.
11. McKay JA, Murray LJ, Curran S, Ross VG, Clark C, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer. 2002. 38:2258–2264.
12. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 2007. 96:1166–1169.
13. Nagahara H, Mimori K, Ohta M, Utsunomiya T, Inoue H, Barnard GF, et al. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res. 2005. 11:1368–1371.
14. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer. 2008. 99:923–929.
15. Park SH, Ha SY, Lee JI, Lee H, Sim H, Kim YS, et al. Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung. J Korean Med Sci. 2009. 24:448–452.
16. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med. 2004. 351:2883.
17. Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005. 11:6650–6656.
TOOLS
Similar articles